Cited by 185Immune cells in cancerCancer, Stress, Anesthesia, and Immune ResponseCancer Cells and Metastasis

G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer

Open access
Hollmén, Maija, Karaman, Sinem, Schwager, Simon, Lisibach, Angela, Christiansen, Ailsa J., Maksimow, Mikael, Varga, Zsuzsanna, Jalkanen, Sirpa +1 more·2016·OncoImmunology

Abstract

Tumor-associated macrophages (TAMs) have been implicated in the promotion of breast cancer growth and metastasis, and a strong infiltration by TAMs has been associated with estrogen receptor (ER)-negative tumors and poor prognosis. However, the molecular mechanisms behind these observations are unclear. We investigated macrophage activation in response to co-culture with several breast cancer cell lines (T47D, MCF-7, BT-474, SKBR-3, Cal-51 and MDA-MB-231) and found that high granulocyte colony-stimulating factor (G-CSF) secretion by the triple-negative breast cancer (TNBC) cell line MDA-MB-231 gave rise to immunosuppressive HLA-DRlo macrophages that promoted migration of breast cancer cells via secretion of TGF-α. In human breast cancer samples (n = 548), G-CSF was highly expressed in TNBC (p < 0.001) and associated with CD163+ macrophages (p < 0.0001), poorer overall survival (OS) (p = 0.021) and significantly increased numbers of TGF-α+ cells. While G-CSF blockade in the 4T1 mammary tumor model promoted maturation of MHCIIhi blood monocytes and TAMs and significantly reduced lung metastasis, anti-CSF-1R treatment promoted MHCIIloF4/80hiMRhi anti-inflammatory TAMs and enhanced lung metastasis in the presence of high G-CSF levels. Combined anti-G-CSF and anti-CSF-1R therapy significantly increased lymph node metastases, possibly via depletion of the so-called “gate-keeper” subcapsular sinus macrophages. These results indicate that G-CSF promotes the anti-inflammatory phenotype of tumor-induced macrophages when CSF-1R is inhibited and therefore caution against the use of M-CSF/CSF-1R targeting agents in tumors with high G-CSF expression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2015.1115177

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 51 · Cited by 185

Authors
Hollmén, M., Karaman, S., Schwager, S., Lisibach, A., Christiansen, A. J., Maksimow, M., Varga, Z., Jalkanen, S., & Detmar, M.
Affiliations
  • ETH Zurich (CH)
  • University of Turku (FI)
  • University Hospital Zurich (CH)
Corresponding author
Detmar, Michael
Venue
OncoImmunology
Published
2015-11-24
Volume
5
Issue
3
Pages
e1115177
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2303301650
Cited by
185
References
51
Citations by year
2026: 10 · 2025: 22 · 2024: 14 · 2023: 17 · 2022: 21 · 2021: 45 · 2020: 19 · 2019: 11 · 2018: 12 · 2017: 10 · 2016: 4
FWCI
4.23
Type
journal article
Language
en
Open access
Locations
  • OncoImmunology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (147087)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Psychiatry and Mental health › Cancer, Stress, Anesthesia, and Immune Response
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
granulocyte colony-stimulating factor, triple-negative breast cancer, tumor-associated macrophages, macrophage phenotype, CSF1R inhibition, transforming growth factor-alpha, CD163+ macrophages, MHC class II, lung metastasis, lymph node metastasis, subcapsular sinus macrophages, immunosuppression, prognostic factors, overall survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review